Melanoma in mice: tryptophan degradation by intestinal Bacteroides limits tumor growth

According to a preclinical study in mice, the degradation of tryptophan into indoles by the TnaA enzyme found in Bacteroides uniformis appears to contribute to a reduction in melanoma size, a type of skin cancer. In humans, patients who respond to immunotherapy (a treatment that stimulates the immune system to fight tumor cells) show a similar trend, although this finding remains to be confirmed.1

Germ-free mouse

A mouse raised in a sterile environment, devoid of any microbiome. Following colonization with a selected bacterial species, this model makes it possible to isolate the effects of that species without interference from other microorganisms.

Immune checkpoint inhibitors

Therapeutic antibodies that target immune system “brakes,” such as CTLA-4 or the PD-1 pathway, to restore the function of anti-tumor T cells.2 CTLA-4 and PD-1 are proteins expressed on the surface of immune cells. Certain tumor cells express PD-L1 on their surface, which binds to PD-1 and activates this “brake”, allowing them to evade the immune response. Anti-PD-1 or anti-PD-L1 antibodies block this interaction.

TCGA (The Cancer Genome Atlas)

A U.S. public program dedicated to the molecular characterization of tumors (including genomic, epigenomic, transcriptomic, and proteomic analyses) across 33 cancer types. The data are publicly available to researchers.3

Cytotoxic T cells (CD8+)

Immune cells capable of recognizing and destroying antigens on the surface of tumor cells; they play a key role in anti-tumor immunity.

Dendritic cells

Immune cells that present antigens—such as those captured from a tumor—to T cells, thereby triggering an immune response.

Antigen

A molecule recognized by the immune system. Tumor antigens, present on the surface of cancer cells, enable T cells to recognize the tumor.

Two Bacteroides species inhibit melanoma growth in mice

In this preclinical study published in Cell Reports Medicine,1 two closely related species, both phenotypically and genetically–Bacteroides rodentium (a murine species) and B. uniformis (a species found in humans)–limit melanoma growth. This anti-tumor effect was observed in several murine models: mice that were initially germ-free (lacking a microbiota) and subsequently colonized with a controlled and defined microbiota; mice with a complex microbiota; and conventional mice. 

In the presence of B. rodentium, tumors contain more CD8+ T cells—also known as cytotoxic T cells because they can destroy tumor cells—and express higher levels of immune-activating genes. In the presence of B. uniformis, the proportion of several CD8+ and CD4+ T cell subpopulations expressing activation markers also increases in the tumor. These T cells play a key role in the the anti-tumor immune response, becoming activated when dendritic cells present them with specific tumor-derived antigens. These results suggest that both of these bacteria promote anti-tumor immunity in mice.

What the mouse experiments show

B. rodentium or B. uniformis

Models : 

- Germ-free mice 

- Mice with complex microbiota 

- Conventional mice

Effect on melanoma size : Decrease.

B. uniformis with a deletion of the tnaA gene

Models : Germ-free mice.

Effect on melanoma size : No decrease.

Indoles administered via gavage

Models : Conventional mice.

Effect on melanoma size : Decrease. 

From tryptophan to indoles: the role of TnaA

Metabolomic analysis revealed lower tryptophan levels in the cecum of mice colonized by B. rodentium compared with control mice. In silico analysis of B. rodentium and B. uniformis genomes identified two enzymes capable of breaking down this amino acid into indoles: tryptophanase A (TnaA), which produces indole, a precursor of indoxyl sulfate; and aromatic aminotransferase (ArAT), which produces indole-3-pyruvate, itself a precursor of indole-3-lactate. In germ-free mice, deletion of the TnaA gene in B. uniformis significantly reduces indole production. At the same time, melanoma size no longer decreases. These findings suggest that the degradation of tryptophan into indole contributes to the anti-tumor effect. The scientists then directly tested four different indole metabolites, administering them to conventional mice by daily gavage (40 mg/kg). This treatment resulted in a reduction in melanoma size, accompanied by greater infiltration of the tumors by cytotoxic CD8+ T cells and other immune cells, including CD11c+ cells (associated with dendritic cells) and F4/80+ cells (a macrophage marker). The mechanism through which indoles influence the immune response at the cellular level remains to be elucidated. These findings suggest that indoles, which are degradation products of tryptophan, can inhibit tumor growth in mice, an effect associated with an enhanced anti-tumor immune response. The authors suggest that a better understanding of how the gut microbiota regulates anti-tumor immunity could open up new therapeutic avenues.

From bacteria to indoles

TnaA

Products : Indole, indoxyl sulfate.

Effect of indole administration on melanoma size in mice : Decrease.

ArAT

Products : Indole-3-pyruvate, indole-3-lactate. 

Effect of indole administration on melanoma size in mice : Decrease. 

A trend that remains to be confirmed in humans

In humans, a reanalysis of previously published data on the fecal microbiota of patients with various types of cancer, including melanoma, using samples collected before treatment with immune checkpoint inhibitors2 (antibodies that release certain “brakes” on the immune system), suggests a similar trend. In one of the cohorts, ArAT gene expression was higher in patients who responded favorably to treatment. For TnaA, which was analyzed across four cohorts, the same trend was observed in two of them, although the differences were not statistically significant. 

In the public TCGA (The Cancer Genome Atlas) database, which includes data on solid tumors, the presence of Bacteroides spp. is associated with better overall survival.3 These observational data in humans demonstrate associations only; they do not establish a direct role for these bacteria in cancer progression. Nevertheless, these findings suggest that future studies should investigate whether administration of ArAT or TnaA, either individually or in combination, could induce anti-tumor immunity and improve patients' responses to oncological treatments.

What the human data show

ArAT gene expression (pre-treatment stool samples)

Analyzed data : One cohort of melanoma patients.

Result : Higher in patients who responded to treatment.

tnaA gene expression (pre-treatment stool samples)

Analyzed data : Four cohorts of melanoma patients.

Result : No significant difference; a trend toward higher abundance in responders was observed in two cohorts.

Bacteroides genus (TCGA—The Cancer Genome Atlas; solid tumors)

Analyzed data : TCGA public database containing genetic and survival data of patients with solid tumors.

Result : Associated with better overall survival.

Declaration of interests

The authors declare that a provisional patent application has been filed covering the findings of this study.

Sources

1. Diaz Olea, X., Beede, K., Pereira, G., Scott, D., Petucci, C., Martens, E., Rodionov, D., Shah, A., Martinez, M.P., Kim, H., Sharma, A.K., Martin, A., Zhang, T., Faries, M.B., Hamid, O., Devkota, S., Osterman, A., Knott, S., Voest, E.E., Ajami, N.J., Wargo, J., Ramer-Tait, A.E. & Ronai, Z.A. (2026). Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth. Cell Reports Medicine, 7(7), 102921. https://doi.org/10.1016/j.xcrm.2026.102921

2. Ribas, A. & Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355. https://doi.org/10.1126/science.aar4060

3. National Cancer Institute. The Cancer Genome Atlas Program (TCGA). 
https://www.cancer.gov/ccg/research/genome-sequencing/tcga (consulté le 23 octobre 2026)

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News On

The Vaginal Microbiome: An Overlooked Factor in Antibiotic Resistance

Your vaginal microbiota is home to a wide variety of microorganisms that contribute to vaginal health. But did you know that it can also contain genes that confer resistance to antibiotics?

Antibiotics are used to treat bacterial infections and have saved millions of lives, including those of pregnant women. But their use, especially when excessive or inappropriate, promotes the selection of resistant bacteria: susceptible bacteria are eliminated, while resistant ones survive, multiply, and become difficult to treat. So much so that bacterial antibiotic resistance has become a major public health issue recognized by the World Health Organization (WHO).

19 Maternal-fetal infections are a major complication of pregnancy, accounting for approximately 19 million cases worldwide in 2021.²

13,4 An estimated 13.4 million babies were born preterm in 2020 (before 37 completed weeks of gestation).²

4,7 Bacterial antimicrobial resistance was estimated to be associated with more than 4.7 million deaths globally in 2021.³

The vaginal microbiota: an overlooked reservoir of antibiotic resistance?

Since these resistances can be transmitted from one bacterium to another through gene exchange, scientists are tracking their presence not only in our environment but also in our bodies, as they can hide in our microbiota. While resistance within the gut, oral, and skin microbiota has already been studied, their presence within the vaginal microbiota remained terra incognita, a field into which a French team (Institut Pasteur, Assistance Publique–Hôpitaux de Paris, Université Paris Cité) ventured. And sure enough: in 56% of the samples collected from the 1,547 pregnant women who participated in the study,1 the researchers detected at least one gene associated with antibiotic resistance.

The vaginal microbiota, a reservoir of antibiotic resistance genes

https://www.biocodexmicrobiotainstitute.com/en/pro/vaginal-microbiota-reservoir…

The composition of the microbiota plays a role

Even more interesting: the bacterial composition of women's vaginal microbiota plays a role. Vaginal microbiota dominated by Lactobacillus crispatus had fewer resistance genes. Conversely, microbiota dominated by Lactobacillus iners or those that were more diverse and low in Lactobacillus exhibited greater diversity in resistance genes and a higher prevalence of mobile genetic elements, which can facilitate the transfer of resistance between bacteria. Researchers classify these communities into different CSTs (types of bacterial communities). CST IV, which has low levels of lactobacilli, is frequently associated with vaginosis, though it is not necessarily pathological. The simultaneous presence of certain bacteria, antibiotic resistance genes, and mobile genetic elements could promote their circulation within the vaginal microbiota, although such transfers were not demonstrated in this study. These findings highlight the importance of studying these communities to better understand vaginal health.

Researchers identify five major types of vaginal communities,⁴ known as CSTs (Community State Types), based on the bacteria that they contain.

  • 3 optimal types in terms of vaginal health, dominated by lactobacilli: CST I, dominated by Lactobacillus crispatus; CST II, dominated by L. gasseri; and CST V, dominated by L. jensenii;
  • 1 suboptimal type, CST III, dominated by another Lactobacillus (L. iners), which is much more susceptible to dysbiosis;
  • and 1 suboptimal type characterized by its low Lactobacillus content (type IV).

A concern for pregnancy?

Researchers have also observed links between certain vaginal microbiota profiles, antibiotic resistance genes, and pregnancy complications. Women who experienced preterm labor or preterm premature rupture of membranes were more likely to exhibit certain changes in the vaginal microbiota, including an increase in bacteria such as E. coli and K. pneumoniae and a decrease in several lactobacilli. These profiles were also associated with changes in antibiotic resistance genes, particularly those associated with β-lactam resistance, in cases of preterm premature rupture of membranes.

And all of this could affect the outcome of the pregnancy: women who experienced complications during childbirth (preterm labor or preterm delivery) had a diverse vaginal microbiota (increased levels of E. coli and K. pneumoniae, a decrease in several species of Lactobacillus) and more genes conferring resistance to β-lactams.

While these results represent a step forward, they must be interpreted with caution: detecting a resistance gene does not mean it is active; the presence of mobile genetic elements suggests exchanges, but the study does not prove that these transfers actually took place; and so on. Further studies will be needed to understand whether these resistances can be transmitted—particularly from mother to newborn—and what their potential health consequences might be. So researchers still have their work cut out for them.

Sources

1. Boutouchent N, Baud A, Tazi A et al. Bacterial community structure shapes the vaginal resistome during pregnancy. npj Biofilms Microbiomes (2026). https://doi.org/10.1038/s41522-026-01144-y. 

2. https://www.who.int/fr/news-room/fact-sheets/detail/preterm-birth.

3. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. 

4. What is vaginal microbiota, what is it made of?. 

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News On

Millets as powerful prebiotics

By Dr. Patrick Uzochukwu Eze¹,², Prof. Lucky Legbosi Nwidu²

¹ Medical Consultant, Seraphic Hospital

² Professor of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Port Harcourt, Nigeria

Prof. Lucky Legbosi Nwidu is recipient of the 2024 Henri Boulard Grant awarded by the Biocodex Microbiota Foundation

Expert opinion 25

Millets have gained renewed scientific attention because they are rich in fibers, resistant starch and polyphenols that may support gut microbiome health. However, social media claims exaggerate their clinical benefits. Current evidence indicates that millets are nutritious whole grains with promising microbiome-modulating properties, but they should not be regarded as “superfoods” capable of restoring the gut microbiome or preventing disease.

Are the claims justified? 

Claims that modern diets “destroy” the gut microbiome and that millets uniquely restore gut health are not supported by strong clinical evidence. Although ultra-processed foods may adversely affect microbial diversity, the gut microbiome is influenced by multiple factors including age, medications, lifestyle and diet. Current human studies do not justify claims that millets alone can restore gut microbiota.

How do millets influence the gut microbiome? 

Millets contain fermentable fibers, resistant starch and polyphenols that reach the gut and are metabolized by beneficial bacteria (Bifidobacterium, Lactobacillus…). Fermentation produces short-chain fatty acids (such as propionate or butyrate), which support gut barrier integrity, immune regulation and metabolic health. Millet polyphenols are converted into bioactive metabolites that may reduce oxidative stress and promote beneficial microbial populations.

Current limitations 

Most evidence come from in vitro experiments, animal studies and small human trials. Although improvements in glycemic control, lipid metabolism and microbial composition have been reported, clinical evidence remains insufficient to conclude that millets uniquely restore the gut microbiome or prevent chronic disease. Elaborate, long-term randomized clinical trials are still needed.

Practical implications

Healthcare professionals should encourage overall diet quality rather than reliance on “superfoods” only. Diets rich in vegetables, fruits, legumes, whole grains, nuts and seeds provide diverse fibers that support a healthy gut microbiome. Millets should be promoted as one nutritious whole-grain option within a balanced diet. Patients should also be cautious against misleading social media claims regarding foods that allegedly “repair the gut” or cure disease.

Conclusion

Millets represent nutritious, climate-resilient whole grains with potential benefits for gut microbiome health. Nevertheless, current clinical evidence supports their use as part of a diverse, plant-rich diet rather than as a unique superfood or cure for disease.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Expert opinion Off

Is the vaginal microbiota a reservoir of resistance genes?

During pregnancy, the vaginal microbiota harbors antibiotic resistance genes and mobile genetic elements. However, this reservoir varies with the composition of the bacterial flora and the outcome of the pregnancy.

Le microbiote vaginal, réservoir de gènes de résistances ?

This is the flip side of the coin when it comes to antibiotics : while their use has saved many lives, it has also gone hand in hand with an increase in resistance. To track down these resistance mechanisms, scientists have turned their attention to various microbiota (gut, skin, etc.), each of which is a potential reservoir. The vaginal microbiota during pregnancy had remained largely unstudied, despite its potential importance for maternal and fetal health, until this study was published in 2026 by a French research team (Institut Pasteur, Assistance Publique–Hôpitaux de Paris, Université Paris Cité).

13,4 An estimated 13.4 million babies were born preterm in 2020 (before 37 completed weeks of gestation).²

Resistance is common and is associated with certain bacterial species

The authors analyzed 1,957 vaginal swabs from 1,547 pregnant women: 56% of the samples contained at least one resistance gene. Which ones were the most abundant? Genes conferring resistance to the macrolide-lincosamide-streptogramin (MLS)* and tetracycline classes of antibiotics. And the most diverse? Those conferring resistance to the β-lactam class. But most importantly: genes for resistance to MLS and tetracycline-class antibiotics were found to be associated with the presence of a wide range of bacterial species, including L. iners** and G. vaginalis. For their part, Enterococcus spp., Streptococcus spp. and Staphylococcus spp. were associated with β-lactam resistance mediated by the mecA or blaZ genes. While these associations involve several species of bacteria in the vaginal microbiota, it wasn’t shown that these bacteria themselves express the genes identified.

* In particular, the lsa(C) gene, which is associated with resistance to certain antibiotics in the MLS family; erm(B), which primarily confers resistance to macrolides and lincosamides; and tet(M), which is associated with resistance to tetracyclines.
** Consistent associations with the MLS resistance genes
lsa and erm, as well as with the tetracycline resistance gene tet.

4,7 Bacterial antimicrobial resistance was estimated to be associated with more than 4.7 million deaths globally in 2021.³

The microbiota influences the resistome

The diversity of resistance genes depended on microbial community types (or CSTs): a vaginal microbiota dominated by L. crispatus (CST I) was associated with a scant and less diverse resistome, suggesting a more limited potential for the spread of resistance. Conversely, communities dominated by L. iners (CST III) or those that were more diverse and low in Lactobacillus (CST IV) exhibited more resistance genes and mobile genetic elements capable of carrying them, suggesting an increased potential for horizontal gene transfer between bacteria.

CSTs (Community State Types) describe different composition profiles of the vaginal microbiota. CST I is dominated by L. crispatus and CST III by L. iners, while CST IV, which is low in lactobacilli, is frequently associated with bacterial vaginosis without being inherently pathological. In this study, L. iners stands out for its associations with genes conferring resistance to MLS and tetracyclines.

The vaginal resistome and obstetric complications

Lastly, the authors identified a resistome signature associated with adverse pregnancy outcomes (preterm labor or preterm delivery with rupture of membranes): this signature is characterized by an increase in Enterobacterales (particularly the bacteria E. coli and K. pneumoniae), a decrease in several Lactobacillus species, and an increase in genes conferring resistance to β-lactams, blaTEM-1 and cfxA in particular. In these women, however, this profile is not sufficient to confirm the presence of an infection. The decrease in lactobacilli is part of a change in bacterial diversity, particularly in the group with preterm premature rupture of membranes.

19 Maternal-fetal infections are a major complication of pregnancy, accounting for approximately 19 million cases worldwide in 2021.¹

The vaginal microbiota thus appears to constitute a structured reservoir of antibiotic resistance genes, contributing to the human resistome overall. However, several questions remain unanswered: Are the resistance genes that are present actually expressed? Are they actually transferred between bacteria? Can they be transmitted to the newborn? These are all questions that will require functional and longitudinal studies. The findings of this team could also open up new possibilities for maternal and neonatal health, although there are no validated clinical applications at this stage.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News On

Vaginal microbiota #25

By Pr. Satu. Pekkala
Academy of Finland Research Fellow, Faculty of Sport,
and Health Science, University of Jyväskylä, Finland

Vaginal microbiota 25

Vaginal microbiome profiles: a potential indicator of preterm birth risk

McKee KS, Bassis CM, Golob J, et al.; ECHO Cohort Consortium. Vaginal microbiome structure in pregnancy and host factors predict preterm birth: Results from the ECHO Cohort.

The vaginal microbiome undergoes changes throughout pregnancy and may help predict the risk of preterm birth. To further investigate this association, researchers analyzed data from 677 pregnant women enrolled in the geographically and demographically diverse U.S. ECHO (Environmental influences on Child Health Outcomes) cohorts, of whom 12% delivered before 37 weeks of gestation.

After adjusting for major maternal factors (including age, ethnicity, education level, and parity), women whose vaginal microbiome was dominated by Lactobacillus crispatus had a lower risk of preterm birth. In contrast, those with a more diverse microbiome (not dominated by lactobacilli) or one predominantly dominated by Lactobacillus iners were at higher risk.

By combining the relative abundance of three key bacterial species (L. crispatus, Gardnerella vaginalis—which is associated with bacterial vaginosis—and Prevotella timonensis) with maternal characteristics, the researchers developed a predictive model with an area under the curve (AUC) of 0.77, a level of performance considered satisfactory by the authors for a clinical prediction tool.

These findings suggest that the vaginal microbiome, when considered alongside maternal factors, could improve obstetric risk stratification and help identify women at increased risk of preterm birth.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Press review Off

Gut microbiota #25

By Pr. Satu. Pekkala
Academy of Finland Research Fellow, Faculty of Sport,
and Health Science, University of Jyväskylä, Finland

Couv press review Mag 18

Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade

Usyk M, Hayes RB, Knight R, et al. Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade.

Immune checkpoint blockade (ICB) can be used to treat high-risk melanoma, but the results vary. About 25–40% of patients still have a recurrence of the disease, and some develop serious side effects. Therefore, better biomarkers are needed to predict who will benefit from the treatment, so that therapy can be tailored to each patient and work more effectively.

Increasing evidence suggests that the gut microbiome influences ICB treatment outcomes in melanoma patients. However, microbes as biomarkers have shown great variability between studies. In this study, fecal samples from 674 patients enrolled in a phase III clinical trial – investigating the combination of nivolumab plus ipilimumab vs. nivolumab alone across five geographic regions – were analyzed to evaluate the predictive potential of the gut microbiome.

Shotgun metagenome sequencing identified bacterial strains linked to recurrence after treatment. Eubacterium, Ruminococcus, Firmicutes, and Clostridium have previously been associated with immune checkpoint therapy outcomes. Eubacterium may enhance immunotherapy via anti-inflammatory effects, while Clostridium and Firmicutes influence T cell-mediated immune regulation. Ruminococcus shows mixed pro- and anti-inflammatory roles. Additional taxa associated with recurrence included Lawsonia, Bariatricus, and Blautia, the latter also previously linked to ICB treatment outcomes. Pathway analysis showed that Eubacterium and Ruminococcus correlated with carbohydrate metabolism that has been formerly linked to the microbiome and cancer treatment success.

Overall, the findings of the study suggest that gut bacterial markers can predict recurrence after adjuvant ICB treatment in melanoma, supporting their potential as clinically valid biomarkers to guide personalized therapy¹.

Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals

Menozzi E, Ren Y, Geiger M, et al. Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals.

Parkinson’s disease (PD) is a leading cause of disability, and its prevalence is growing fast worldwide. In PD, dopaminergic neurons of the substantia nigra are lost and aggregated -synuclein accumulate in brainstem and cortical regions. PD symptoms can be treated with levodopa, but to slow or prevent severe disability, early detection of individuals at risk would be crucial.

Genetic variants in the GBA1 gene, encoding glucocerebrosidase, are found in about 15% of PD cases. Evidence also supports the role of the microbiota-gut-brain axis in PD, and microbiome analysis might enable identification of healthy individuals at higher risk of neurodegeneration.

This cross-sectional, multicenter study analyzed patients with PD carrying a GBA1 gene variant, patients with PD not carrying the variant, healthy controls, and non-manifesting carriers of a GBA1 variant (i.e., not diagnosed with PD). A total of 540 participants were included.

Compared to healthy controls, non-manifesting carriers presented worse motor symptoms. Being a carrier or non-carrier of a GBA1 variant did not influence the microbiome, whereas beta-diversity difference between healthy controls and either group was significant. The authors then pooled all patients with PD regardless of their genetic status to identify a PD microbiome signature with an optimally powered analysis. In PD, Actinobacteriota, Bifidobacteriaceae, Streptococcus mutans, Bifidobacterium longum, Bifidobacterium dentium, and Lactobacillus paragasseri were enriched among many other taxa. In total, over 25% of the microbiome was altered compared to healthy controls.

An interesting finding was that the microbiome of non-manifesting carriers of a GBA1 variant was an "intermediate" between healthy controls and patients with PD. This was associated with disease progression and symptoms indicative of future development of PD. The same phenomenon was reproduced in three independent cohorts from the United States, Korea, and Turkey.

The authors reckon that gut microbiomes could be used to identify both genetically and non-genetically at-risk individuals who may be progressing toward PD and serve as an early disease marker¹.

Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals

Baldanzi G, Larsson A, Sayols-Baixeras S, et al. Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.

Recurrent and long-term use of antibiotics is associated with many non-communicable diseases likely due to alterations in gut microbiome. Known short-term alterations include decrease in diversity and increased abundance of potential pathogens. However, large population-based investigations examining the long-term effects of antibiotics on gut microbiomes have not been conducted.

This study combined individual-level data from the Swedish Prescribed Drug Register with fecal metagenomes of 14,979 adults to investigate the associations between oral antibiotic use over 8 years and gut microbiome. Participants using antibiotics at the time of sampling or with an ongoing infection were excluded.

The authors observed that gut microbiome diversity decreased with each additional antibiotic course within three periods: < 1 year, 1–4 years and 4–8 years before fecal sampling. Of the different antibiotics, clindamycin, fluoroquinolones and flucloxacillin had the largest effect on diversity, whereas no associations were detected for extended-spectrum penicillins. Even a single course of tetracyclines, flucloxacillin, fluoroquinolones, clindamycin, sulfamethoxazole-trimethoprim, cephalosporins or macrolides less than 4 years or 4–8 years before sampling caused reduced diversity.

Taxonomically, use of clindamycin, fluoroquinolones and flucloxacillin was associated with a greater abundance of Enterocloster bolteae, E. citroniae, Flavonifractor plautii, Ruminococcus B gnavus and Eggerthella lenta, species previously associated with cardiometabolic risks. Overall, species negatively associated with antibiotic use were associated with better cardiometabolic and inflammatory outcomes.

The authors conclude that their results could inform future guidelines on outpatient antimicrobial practices, which should prioritize antibiotics that have a lower impact on the gut microbiome¹.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Press review Off

Why do different people behave differently to probiotics?

. Sourav Goswami 

. Alisha Ansari 

. Dr. Tarini Shankar Ghosh 

Indraprastha Institute of Information Technology Delhi, India

Sourav Goswami and Alisha Ansari are joint first authors and PhD scholars working in the Microbiome Informatics Lab, headed by Dr. Tarini Shankar Ghosh, in the Department of Computational Biology at the Indraprastha Institute of Information Technology (IIIT-Delhi), India. Their work focuses on large-scale, multi-cohort microbiome analysis, probiotic science, and building data-driven tools that translate population-level patterns into personalized predictions.

Congress review 2026

When probiotics meet the gut microbiome

Walk into any pharmacy and you will find an entire shelf devoted to probiotics. Among the most common are Bifidobacterium species, marketed for gut health, immune support, healthy aging, and an expanding range of clinical conditions. Yet probiotic benefits sharply differ among individuals. Clinical trials consistently show that while some people experience clear and lasting improvements, others derive little or no benefit.

One reason could be the persistence of the probiotic in the individual's gut, which could be influenced by the gut microbiome that already exists before a probiotic is consumed. Think of it like a new tenant moving into a crowded building: the incoming bacterium has to compete for resources and find its place among microbes that were already there. Its ability to colonize and persist depends not just on its own traits but on the resident community it walks into.

Previous studies had implicated baseline microbiome composition in probiotic engraftment, but they were limited to small cohorts and individual strains, leaving open whether microbiome features can reliably predict probiotic success. In this study, we address this question through the largest global meta-analysis of its kind, identifying the microbial features that shape Bifidobacterium colonization and introducing a framework to predict an individual's receptiveness to probiotic treatment¹.

Bifidobacteria keep selective company

Investigating 51,244 gut microbiomes (from 149 study-cohorts across 45 countries), we observed consistent sets of bacteria being associated with specific Bifidobacterium. Butyrate producers and members of the genus Collinsella tended to show consistent positive links with certain Bifidobacteria, while certain pathobiont Firmicutes and Bacteroidota behaved negatively. We captured these patterns as Association-Scores, a measure of how reliably a microbe accompanies a given Bifidobacterium.

These scores were stable: when recalculated across different diseases and compared against apparently non-diseased individuals, the associations largely held, and the same was true after adjusting for host properties like diet, medication, clinical factors, and also for certain microbiome properties. Bacteria "helping" Bifidobacterium in healthy guts tended to do so in sick ones too, which points to a real microbial relationship rather than side effects of illness itself. Mapping only the associations that passed all checks revealed a compact, consistent pattern: Collinsella and a handful of oral, Bacteroidetes, and Firmicutes groups linked reliably to specific bifidobacteria, no matter which lens was used to look for them¹.

Image
Figure 1 FOCUS

The Receptive-Score

We then asked whether these patterns could predict something practical: whether a probiotic actually persists after someone takes it? We developed the Receptive-Score, which measures how welcoming a baseline microbiome is to a specific Bifidobacterium using its known microbial associates and baseline abundance.

Investigating eight independent probiotic trials, the Receptive-Score combined with baseline Bifidobacterium levels correctly predicted post-treatment persistence or increase in 69.23% of trial-probiotic combinations. In a B. longum trial², people who became persisters had significantly higher baseline Receptive-Scores than non-persisters. In two trials³,⁴ with clinical follow-up, higher scores also lined up with better clinical outcomes, including fewer gastrointestinal symptoms and lower inflammation markers, though sample sizes were too small for firm conclusions there.

What the genes reveal

To understand what might drive these relationships, we examined the genomes of 66 non-Bifidobacterium taxa. We identified specific genes and metabolic pathways in bacteria that showed strong positive associations with the health-associated B. adolescentis and B. longum, revealing a cooperative cross-feeding network. Many of these bacteria encoded enzymes involved in the breakdown of complex dietary carbohydrates and the production of metabolites such as acetate that can be exchanged within the microbial community, creating a nutrient-rich environment that supports Bifidobacterium persistence.

In contrast, bacteria associated with B. breve and B. dentium were enriched for genes involved in metal ion acquisition and scavenging, suggesting adaptation to resource competition and inflammatory conditions rather than metabolic cooperation. These findings indicate that the ability of different Bifidobacterium species to colonize in the gut may depend not only on their own biology but also on the metabolic capabilities of their microbial neighbours.

Predicting how your gut microbes will change

While the study still has certain gaps (limited representation of non-industrialized populations, species-level investigations while probiotics are typically characterized at strain level, limited data on clinical outcomes), this framework of capturing the receptivity of a microbiome to a given microbe can be generalized to build "digital twin" models of a person's gut community that let scientists test probiotics, dietary changes, or other microbial therapies in silico before ever trying them on an actual patient

Key points

  • A gut's existing bacteria shape whether a Bifidobacterium probiotic will persist.
  • Receptive-Scores predicted persistence in 69.23% of trial-probiotic pairs tested.
  • Analysis of functional signature linked to these association patterns identifies cross-feeding as a likely mechanism.

Conclusion

This work shows that a person's existing gut bacteria actively gatekeep whether a probiotic takes hold. Reading that baseline community may one day help clinicians choose the right Bifidobacterial strain for the right person, rather than relying on trial and error.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Congress review Off

Highlights from the ESPGHAN 2026

By Prof. Erick Manuel Toro Monjaraz

Instituto Nacional de Pediatría, INP Department of Gastroenterology, Mexico City, Mexico

ESPEGHAN 2026

From June 24 to 27, the 58th edition of the Annual Congress of the European Society of Paediatric Gastroenterology, Hepatology, and Nutrition was held in Lille, France. This congress brings together pediatric gastroenterologists, hepatologists, and nutritionists from around the world, making it one of the most important congresses in these paediatric specialties.

Rome V criteria and its presentation at ESPGHAN

Among the topics presented, the one that generated the most anticipation was the presentation of the pediatric Rome V criteria, and this was evidenced by the large number of people who filled the auditorium, leaving many outside, and with an online broadcast. The Rome V criteria differ from the Rome IV criteria in that they divide the pathologies of the upper and lower digestive tracts, in addition to removing the age division. Dr. Samuel Nurko introduced these criteria, and together with Drs. Rachel Rosen, Miguel Saps, but were, with Rome V, added to the pediatric section. Additionally, supragastric belching and aerophagia were included, as well as pediatric feeding disorders, which contributes to the classification of these pathologies that are common in daily pediatric consultations. In pain disorders, Dr. Di Lorenzo emphasized the inclusion of centrally mediated abdominal pain, a disorder included in the adult section, but which had not yet taken a significant role in the pediatric section. This entity, unlike other abdominal pain disorders, is continuous, debilitating, and from the outset requires multidisciplinary treatment to help this group of patients. Undoubtedly, a disorder that will require further research to understand its pathophysiology and treatment. Finally, biliary pain, which, although not common in pediatrics, should be considered when we have patients with pain in the right upper quadrant and no stones or pathology that explains the origin of the pain¹,².

Without any doubt, the Rome V criteria were an important part of this congress; however, other presentations and papers were highly compelling, especially regarding gut microbiota.

Probiotics for hyperbilirubinemia in newborns

A randomized clinical trial evaluated the effect of supplementation with Bifidobacterium breve M-16V and Bifidobacterium animalis subsp. lactis Bb-12 as an adjunct treatment to phototherapy in 79 newborns with neonatal jaundice. The objective was to determine if the modulation of the gut microbiota could improve the clinical response and counteract the dysbiosis induced by phototherapy.

Neonates who received probiotics had a higher frequency of bowel movements and a faster reduction in transcutaneous bilirubin levels compared to those treated solely with phototherapy. Additionally, a trend toward shorter hospital stays and better motor and language development scores between 18 and 24 months was observed, although these differences did not reach statistical significance.

The analysis of the microbiota showed an increase in bacterial diversity, a higher abundance of Bifidobacterium breve, and an increase in the Bifidobacterium/Escherichia coli ratio. Likewise, the metabolomic analysis revealed a profile compatible with increased DNA synthesis, cell growth, and regulation of the inflammatory response, suggesting a possible role of the microbiota in bilirubin metabolism and neurodevelopment.

Overall, these findings support the potential of Bifidobacterium M-16V and Bb-12 strains as a complement to phototherapy to promote the restoration of gut microbiota and optimize bilirubin clearance. However, multicenter studies with larger sample sizes are required to confirm these benefits and define their incorporation into clinical practice³.

Microbiota as a tool for predicting late-onset sepsis in newborns

A multicenter case-control study evaluated whether the intestinal microbiota profile can early identify very premature newborns at risk of developing late-onset sepsis (LOS). Faecal samples from 58 infants with LOS confirmed by blood culture and 58 matched controls, obtained up to 10 days before the clinical onset of the infection, were analyzed using 16S rRNA gene sequencing.

The changes in the microbiota were closely related to the microorganisms causing sepsis. Cases of LOS caused by Escherichia coli and other non-staphylococcal pathogens showed a progressive increase in Escherichia/Shigella before the onset of symptoms. A predictive model based on machine learning (Random Forest) showed excellent performance in identifying LOS due to E. coli in the development cohort, although its performance decreased in the external validation cohorts.

The authors conclude that the intestinal microbiota profile could become a promising tool for early detection, especially of E. coli sepsis, which would open the possibility of implementing preventive strategies and targeted interventions in high-risk premature newborns. However, additional studies are required to improve and validate these predictive models before their clinical application⁴.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Congress review Off

Gut micro-organisms associated with health, nutrition and dietary interventions

COMMENTED ARTICLE - Adult’ section

By Prof. Harry Sokol Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France 

Comments on the article by Asnicar et al. Nature 2026¹ 

Adult commented article

The incidence of cardiometabolic diseases is increasing globally, with both poor diet and the human gut microbiome implicated. However, large-scale comprehensive studies exploring these links in diverse populations are lacking in this area. Using data from over 34,000 participants in the US and the UK, this study highlights significant associations between diet, the gut microbiome and cardiometabolic health markers. The authors have established “ZOE Microbiome Health Ranking 2025” to rank the species most and least favourably associated with human health markers, validated in over 7,800 independent samples. In dietary interventional clinical trials (746 participants), favourable species increased while unfavourable species decreased. These findings strengthen the link between diet, the microbiome and health, whilst emphasising that prospective and interventional studies are still needed to establish a causal link.

What do we already know about this subject?

 Cardiometabolic diseases, particularly cardiovascular disease and type 2 diabetes, are the leading cause of morbidity and mortality in Western countries². Whilst diet is the main modifiable risk factor, the gut microbiome is now recognised as playing a key role in metabolism, due to its influence on diet and involvement in obesity, as well as insulin resistance and inflammation. However, studies available up to now have been based mainly on small and lowly diversified cohorts, with limited microbiological and phenotypic data³⁻⁵, which has hindered the identification of robust and universal microbial biomarkers and definition of a “healthy microbiome” applicable at a population level.

What are the main insights from this study?

To answer these questions, the authors pooled and harmonised five metagenomic cohorts (United States and United Kingdom), representing a total of 34,694 participants with high-depth shotgun metagenomic sequencing, validated diet questionnaires, and a complete panel of cardiometabolic markers. Using machine-learning models trained on the relative abundance of 661 microbial species (defined as species-level genome bins, or SGBs), the authors showed that the microbiome reproducibly, albeit moderately, predicts numerous cardiometabolic health markers [AUC 0.64–0.73 for classification; Spearman’s correlation coefficient 0.30–0.46 for regression analysis (figure 1)].

These findings led to the creation of “ZOE Microbiome Health Ranking 2025”, a ranking system for 661 species based on their clear link to host health markers (personal health, fasting markers, postprandial markers) and diet quality. The highest-ranked species (close to 0), which are associated with a favourable metabolic profile, belong mainly to the phylum Firmicutes and Clostridia and Ruminococcaceae classes, but most are uncharacterised. Of the top 50 species, 22 were unknown organisms represented solely by genomes reconstructed from metagenomic data. Among the known species, Faecalibacterium prausnitzii and Eubacterium siraeum are classified in the most favourable category, a finding consistent with the literature. Conversely, the lowest-ranked species (close to 1), which are associated with an unfavourable profile, include organisms already known for their harmful effects such as Ruminococcus gnavus, Ruminococcus torques, Flavonifractor plautii, Enterocloster bolteae and Eggerthella lenta.

The authors then validated this classification using over 7,800 independent public samples. On average, obese individuals had 1.95 more unfavourable species than normal-weight individuals, and 5.2 fewer favourable species. Finally, in two clinical trials on dietary intervention (n = 746), favourably ranked species increased in abundance and prevalence after the intervention, whilst unfavourable species decreased, suggesting that the microbiome can be modified by diet, even though causality cannot be inferred.

Image
Figure 1 SOKOL

What are the consequences in practice?

This study confirmed, on a large scale, that the gut microbiome is a measurable and modifiable factor in cardiometabolic health, and that “ZOE MB Health Ranking 2025” is a stratification tool that could potentially be used to guide personalised dietary recommendations. It could also be used as an intermediate endpoint in future trials. The immediate clinical implications remain limited given that the associations are correlational, no direct mechanism has been demonstrated, and causality will need to be established in randomised controlled trials. The researchers believe that 22 of the top 50 species remain totally uncharacterised, therefore, cultivating and identifying their metabolites are a priority. The study also calls for the systematic use of shotgun metagenomics in large-scale epidemiological studies.

Key points

  • This is the largest metagenomic study combining dietary and clinical data 
  • Most taxa associated with good health are yet to be cultivated and lack a phenotypic description, highlighting a major blind spot in microbiome research
  •  Favourable species increase and unfavourable species decrease with improved diet, providing proof of concept of their modifiable nature, but not of causality

Conclusion

This study is a significant methodological advance in the field of nutritional metagenomics, providing a microbial ranking system that is reproducible on a large scale, across different populations. It confirms the relevance of the microbiome as a marker associated with cardiometabolic health and strengthens the assumption that diet can be used to modulate the microbiome. However, it does not conclude that the microbiome plays a causal role in cardiometabolic disease, and its direct therapeutic implications are speculative in the absence of dedicated interventional trials. The main value of this research is perhaps the provision of the mapping and assumptions required to design such trials in an informed manner.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Commented article Off